Author: Denovo Biopharma

Posted Date:

April 29, 2026

Denovo Announces Issuance of U.S. Patent of Novel Genetic Biomarker ANK3 (DGM4™) for Liafensine (DB104)

Denovo Biopharma

April 29, 2026
Denovo Biopharma Announces Partnership with Orygen on Phase 2 Study Evaluating DB103 (Pomaglumetad Methionil) in Treating Psychosis

Denovo Biopharma

February 11, 2026